Thrombogenic Mechanisms of Antiphospholipid Antibodies

Naomi L Esmon; Mikhail D Smirnov; Charles T Esmon

doi:10.1055/s-0038-1657505

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 78(01): 079-082
DOI: 10.1055/s-0038-1657505

Antiphospholipid antibodies

Schattauer GmbH Stuttgart

Thrombogenic Mechanisms of Antiphospholipid Antibodies

Naomi L Esmon

Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA

,

Mikhail D Smirnov

Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA

,

Charles T Esmon

Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA

› Author Affiliations

Abstract

PDF Download

PDF (723 kb)

References

References
1 Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?. Arch Pathol Lab Med 1993; 117: 78-88
2 Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulants and thrombosis: The role of phospholipids. [In Press] Haematologia. 1997
3 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854-2867
4 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-360
5 Mohan Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-4182
6 Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W. et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-825
7 Arvieux J, Damige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-1125
8 Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994; 71: 670-674
9 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-210
10 Stegnar M, Bozic B, Peternel P, Kveder T, Vene N, Rozman B. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thromb Res 1991; 63: 433-443
11 Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G. Molecular diversity and implications for disease. Arthritis Rheum 1995; 38: 306-314
12 Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcgamma receptor IIA and Fcgamma receptor IIIB: Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274-1281
13 Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: Development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992; 67: 507-509
14 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625
15 Bokarewa M. Phospholipid antibodies and APC resistance phenomenon in patients with thrombosis. Ph.D Thesis. Karolinska Institute. 1995
16 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Hematol 1992; 29: 213-226
17 Berard M, Chantome R, Marcelli A, Boffa M-C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies.I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23: 1369-1374
18 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819
19 Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-316
20 Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 1996; 81: 419-426
21 Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VHa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-13993
22 Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem 1995; 270: 18500-18505
23 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518
24 Smirnov M, Rezaie AR, Regan LM, Esmon CT, Esmon NL. The PE dependence of activated protein C function is mediated through the gla-domain. [Abstract] Circulation 1996; 94: 001-694
25 Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75: 344-349
26 Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5: 141-148